Trial Profile
Phase II study of PEGPH20 in combination with gemcitabine and nab-paclitaxel in patients with borderline resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2015
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary)
- Indications Adenocarcinoma
- Focus Therapeutic Use
- 12 Aug 2015 New trial record